ArticleFrontiers in pediatrics2024

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.

Yaacov Frishberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.